TickerFacts.

Myriad Genetics Inc (MYGN): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$338.60M
As of 2025-12-31
$335.00M
As of 2026-06-30
+2.7%
3-year compound annual growth
-8.8%
5-year compound annual growth
$537.80M2010-06-30: $36.27M2011-06-30: $44.03M2012-06-30: $54.98M2013-06-30: $75.23M2014-06-30: $104.80M2015-06-30: $104.10M2016-06-30: $132.40M2017-06-30: $440.90M2018-06-30: $209.20M2019-06-30: $473.80M2020-06-30: $486.40M2020-12-31: $537.80M2021-12-31: $352.90M2022-12-31: $312.90M2023-12-31: $363.30M2024-12-31: $326.50M2025-12-31: $338.60M$338.60M
2010-06-30 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$338.60M+3.7%2026-02-24, Balance as of period end
2024-12-31$326.50M-10.1%2026-02-24, Balance as of period end
2023-12-31$363.30M+16.1%2025-02-28, Balance as of period end
2022-12-31$312.90M-11.3%2024-02-28, Balance as of period end
2021-12-31$352.90M-34.4%2023-03-01, Balance as of period end
2020-12-31$537.80Mn/a2022-02-25, Balance as of period end
2020-06-30$486.40M+2.7%2020-08-13, Balance as of period end
2019-06-30$473.80M+126.5%2020-08-13, Balance as of period end
2018-06-30$209.20M-52.6%2019-08-13, Balance as of period end
2017-06-30$440.90Mn/c2018-08-24, Balance as of period end
2016-06-30$132.40M+27.2%2017-08-09, Balance as of period end
2015-06-30$104.10M-0.7%2016-08-10, Balance as of period end
2014-06-30$104.80M+39.3%2015-08-12, Balance as of period end
2013-06-30$75.23M+36.8%2014-08-13, Balance as of period end
2012-06-30$54.98M+24.8%2013-08-14, Balance as of period end
2011-06-30$44.03M+21.4%2012-08-15, Balance as of period end
2010-06-30$36.27Mn/a2011-08-15, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Myriad Genetics Inc (MYGN)2025-12-31$338.60M+3.7%
Neogen Corp (NEOG)2026-05-31$1.25B-8.7%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.14B+27.5%
QuidelOrtho Corp (QDEL)2025-12-28$3.85B+11.9%
Idexx Laboratories Inc (IDXX)2025-12-31$1.75B+2.8%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$170.73M-46.5%
Alpha Teknova, Inc. (TKNO)2025-12-31$34.81M-4.3%
Immucell Corp (ICCC)2025-12-31$15.48M-12.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$12.39M+53.8%

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗